SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 163 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.68 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,588 | -22.5% | 1,900 | +11.8% | 0.00% | – |
| Q2 2023 | $35,581 | +17.2% | 1,700 | +18.2% | 0.00% | – |
| Q1 2023 | $30,371 | -16.1% | 1,438 | +0.9% | 0.00% | – |
| Q4 2022 | $36,180 | +16.7% | 1,425 | +11.8% | 0.00% | – |
| Q3 2022 | $31,000 | +29.2% | 1,275 | 0.0% | 0.00% | – |
| Q2 2022 | $24,000 | +9.1% | 1,275 | +2.0% | 0.00% | – |
| Q1 2022 | $22,000 | +340.0% | 1,250 | +400.0% | 0.00% | – |
| Q4 2021 | $5,000 | -77.3% | 250 | -87.5% | 0.00% | – |
| Q1 2020 | $22,000 | – | 2,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |